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dosed RAAS blockade, without inducing hypophosphate-
mia using a forced uptitration treatment regimen aimed at 
restricting phosphate uptake.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease (CKD) is an independent risk 
factor for cardiovascular morbidity and mortality. The 
putative mechanisms of cardiovascular damage cannot 
just be explained by traditional risk factors. Currently, 
treatment of these risk factors, like dyslipidemia and dia-
betes, does not improve survival in patients with CKD. 
Moreover, intensive glycemic control might increase 
mortality in patients with diabetic nephropathy  [1, 2] . 
Therefore, there is a real need for new treatment targets to 
improve cardiovascular outcomes. Deregulations in min-
eral metabolism such as hyperphosphatemia and vitamin 
D deficiency are common in CKD patients and have been 
strongly associated with an increased mortality risk  [3–5] . 
Thus, serum phosphate and vitamin D have been pro-
posed as targets for intervention to improve cardiovascu-
lar outcomes in CKD. Yet, serum phosphate in itself does 
 Key Words 
 Fibroblast growth factor-23 · Sevelamer · Chronic kidney 
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 Abstract 
 Background: Increased levels of phosphate and fibroblast 
growth factor-23 (FGF23) are strong predictors of cardiovas-
cular morbidity and mortality in patients with chronic kidney 
disease (CKD). Preliminary data suggest that interventions 
lowering gastro-intestinal phosphate uptake lowers serum 
FGF23 concentrations and improves cardiovascular risk and 
subsequently survival. However, data are lacking about the 
magnitude of effects, the effect in different stages of CKD 
and whether there is a dose–effect relationship.  Methods: 
Therefore, the Sevelamer on FGF23 Trial (SoFT) is designed 
as an open-label, single-arm, clinical pilot study aiming to 
demonstrate the feasibility of a phosphate-restricted diet in 
combination with the phosphate binder sevelamer to in-
duce an effective, predictable and sustained decrease in 
FGF23 level in patients with an estimated glomerular filtra-
tion rate (eGFR) of 15–90 or >90 ml/min/1.73 m 2 with pro-
teinuria >1.0 g in 24 h urine collection, despite optimally 
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not seem to be the most obvious target, since the increased 
cardiovascular risk is already present in early stages where 
phosphate levels are still within the normal range  [6] . Fur-
thermore, there is no evidence that supplementation with 
vitamin D improves clinical outcome  [7] , and for phos-
phate lowering therapy, despite decades of application, a 
definitive proof for improved clinical outcome is lacking. 
Therefore, additional factors related to mineral metabo-
lism may be more suitable targets for intervention.
 Fibroblast growth factor-23 (FGF23) regulates phos-
phate and vitamin D metabolism through its strong 
 phosphaturic action and inhibition of vitamin D 1α- hy-
droxylase activity in proximal tubuli  [8, 9] . It is secreted 
by osteocytes and osteoblasts, for instance, in response to 
oral phosphate loading or increased serum 1,25(OH) 2 D 3 
levels  [10–12] . Plasma FGF23 increases as CKD progress-
es  [13, 14] . At the same time, responsiveness to FGF23 
declines as the number of intact nephrons declines. In 
advanced stages of CKD, increased FGF23 levels fail to 
further increase the fractional urinary excretion of phos-
phate, resulting in overt hyperphosphatemia.
 In epidemiologic studies, high concentrations of 
FGF23 have been associated with progressive renal func-
tion loss in diabetic and non-diabetic CKD  [15, 16], with 
an increased risk of cardiovascular morbidity and mortal-
ity  [14, 17–19] . The relationship between FGF23 and car-
diovascular risk is further supported by epidemiological 
studies in which elevated FGF23 was associated with en-
dothelial dysfunction  [20, 21] , total body atherosclerosis 
 [22] and LVH  [23–25] . However, these studies were not 
able to prove whether FGF23 directly contributes to a 
higher cardiovascular risk or rather FGF23 represents an 
‘innocent bystander’ reflecting toxicity of other factors, 
such as phosphate itself. Recent mechanistic data how-
ever are highly suggestive of a direct dismal effect of 
FGF23 on the cardiovascular system. The study by Faul et 
al.  [26] showed that increased circulating FGF23 in ani-
mal models, with or without CKD, induced LVH through 
a direct effect on the cardiomyocytes. The animal study of 
Andrukhova et al.  [27] showed that an increase in FGF23 
leads to increased sodium uptake in the distal tubular cells 
leading to volume expansion, hypertension and hypertro-
phy of the heart. Recent observations in humans are in 
line with the hypothesis that FGF23 can have pathological 
effects on the cardiovascular system  [21, 28] , particularly 
through volume overload-related cardiovascular compli-
cations, more than atherosclerotic events  [29] .
 These epidemiological and mechanistic studies justify 
targeting FGF23 in subsequent clinical studies to eluci-
date whether improvements of circulating FGF23 levels 
will translate into improved clinical end points. However, 
prior to executing such trials, detailed knowledge is re-
quired about dose–response effects of FGF23-modulat-
ing interventions on FGF23 concentrations in CKD.
 Principle therapeutic maneuvers to lower FGF23 are 
dietary phosphate restriction, phosphate binder therapy 
and, as recently shown, calcimimetic therapy in dialysis-
dependent stage V CKD  [30] . Some small studies suggest 
that FGF23 can be reduced by dietary phosphate restric-
tion and/or phosphate binding therapy. However, data 
are still inconsistent, which may relate to differences in 
the regimen, duration of treatment or patient character-
istics  [10, 31–33] . In addition, data are lacking about the 
magnitude of effects, the potency of phosphate binder 
therapy to reduce FGF23 in different stages of CKD and 
the presence or absence of a dose–effect relationship. On 
top of that, as our data showed that proteinuria is associ-
ated with FGF23 levels  [34] , it is unknown how protein-
uria interacts with the FGF23-lowering potency of phos-
phate binder therapy. To address these issues, the 
Sevelamer on FGF23 Trial (SoFT) study was designed as 
an open-label, single-arm, clinical pilot study aiming to 
demonstrate the feasibility to induce an effective, predict-
able and sustained decrease in FGF23 level in patients 
with an estimated glomerular filtration rate (eGFR) of 
15–90 or >90 ml/min/1.73 m 2 with proteinuria >1.0 g in 
24 h urine collection, despite optimally dosed RAAS 
blockade, without inducing hypophosphatemia using a 
forced uptitration treatment regimen aimed at restricting 
phosphate uptake. We expect that instead of being titrat-
ed to a specific value of phosphate, a combination of di-
etary phosphate restriction and non-calcium-based bind-
ers can induce a decline of FGF23. For this, our hypoth-
esis is that doses are needed that go beyond what is 
needed for phosphate control. If this is confirmed in the 
SoFT trial, this strategy can be applied to target FGF23 to 
test the hypothesis that a decline of FGF23, instead of 
phosphate, can lead to improvement of risk.
 Study Protocol 
 Study Design and Organization 
 The SoFT is an investigator-initiated, prospective, multicenter, 
open-label, single-arm trial in subjects with an eGFR of 15–90 or 
>90 ml/min/1.73 m 2 with proteinuria >1.0 g in 24 h urine collec-
tion, despite optimally dosed RAAS blockade. The study is being 
conducted according to the principles of the Declaration of Hel-
sinki and in accordance with the Medical Research Involving Hu-
man Subjects Act (WMO, The Netherlands). The study has been 
approved by the Medical Ethical Committee of the VU University 
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Participation in the study is on voluntary basis. Patients will not 
receive any financial support or priority for treatment of other dis-
eases during this study.
 Study Population 
 The SoFT study recruits patients  ≥ 18 years, with CKD stage I 
with >1 g proteinuria in 24 h urine collection despite optimally 
dosed RAAS blockade and CKD stages II–IV, with a serum phos-
phate level between 0.80 and 1.45 mmol/l and not taking any phos-
phate binder therapy. Patients are stratified according to CKD 
stages (KDIGO clinical practice guideline for the evaluation and 
management of CKD of 2012)  [35] . Furthermore, eligible patients 
were not allowed to start vitamin D suppletion or change their vi-
tamin D dose within 4 weeks prior to start of the study or during 
the study, as this might interfere with the study end point. Patients 
who also met the other prespecified eligibility criteria ( table 1 ) and 
provided written informed consent were enrolled. Patient enrol-
ment started during February 2014 and is ongoing.
 Intervention 
 All patients already receive standard care before inclusion, which 
includes an advice to restrict sodium intake to <100 mmol Na + /day, 
statin therapy when LDL cholesterol >2.5 mmol/l, antihypertensive 
treatment (defined as a systolic blood pressure  ≥ 140 mm Hg and/or 
a diastolic blood pressure  ≥ 90 mm Hg), using ACE inhibitors or 
ARBs in case of proteinuria above 0.5 g/24 h and using glucose-
lowering drugs if indicated (according to the Dutch Guideline Car-
diovascular Risk Management 2006). At baseline, all the patients are 
placed on a phosphate-restricted diet aimed at a phosphate intake 
<1,000 mg/day guided by instructions of a dietician. Afterward, the 
researcher will examine the dietary compliance of phosphate and 
sodium restriction at every visit. After the second week, all patients 
initiate treatment with 1,600 mg sevelamer carbonate per day in di-
vided doses, which is uptitrated with 2 weekly increments from 
1,600 mg to daily dosages of 3,200; 4,800; 6,400 and 8,000 mg, pro-
vided the serum phosphate concentrations do not drop below 0.8 
mmol/l. When the highest tolerable dose is reached, based on serum 
phosphate concentration and side effects, that dose will be main-
tained for 6 weeks, after which sevelamer and dietary intervention 
are stopped ( fig. 1 ). The total study period is 18 weeks.
 Clinical Laboratory Tests 
 Serum phosphate as well as concentrations of protein, creati-
nine, phosphate sodium, and calcium in first morning spot urine 
are measured every study visit. A tube containing a protease in-
hibitor is being drawn every study visit and stored in the freezer in 
order to measure cFGF23 concentrations at the end of the study. 
cFGF23 will be measured with Elisa kits (Immutopics, Inc., San 
Clemente, Calif., USA), following manufacturer’s protocols with 
intra-assay variation of <5% and inter-assay variation of <10%. 
Once a month, serum creatinine, sodium, potassium, calcium, glu-
cose and albumin concentrations are measured. Total blood count, 
serum 25(OH) 2 D 3 and parathyroid hormone levels are measured 
at baseline and week 16 of the study; 24-hour urine will be col-
lected as well at these 2 visits to measure concentrations of phos-
phate, creatinine, protein, urea, calcium and sodium. At baseline 
and at the end of the study serum, EDTA-plasma, heparin-plasma 
and urine will be stored for post hoc studies.
 Safety 
 In general, the risk for participation in this study is estimated 
to be low. Sevelamer carbonate is widely prescribed in the clinical 
setting for the treatment of hyperphosphatemia in CKD patients. 
No serious side effects are expected of the sevelamer carbonate 
dosages used in this study. Gastrointestinal complaints like nausea, 
vomiting, constipation or diarrhea are the most likely side effects 
Table 1.  Eligibility criteria of the SoFT study
Inclusion criteria Exclusion criteria
Male and female patients Use of antiarrhythmic agents or anticonvulsants
eGFR of 15–90 or >90 ml/min/1.73 m2 with proteinuria >1.0 g in 
24 h urine collection, despite optimally dosed RAAS blockade
Patients with >1.0 g proteinuria in 24 h urine collection not 
receiving RAAS blockade therapy
Age ≥18 years Patients taking other experimental (i.e. non marketed) therapies
Serum phosphate levels between 0.80 and 1.45 mmol/l Pregnant or nursing (lactating) women, where pregnancy is 
defined as a state of a female after conception and until the 
termination of gestation, confirmed by a positive β-HCG urine 
test (>5 U/l)
Not taking any phosphate binding therapy Change in vitamin D dose 4 weeks prior to baseline
Informed consent provided History of parathyroidectomy, arrhythmias, seizures, bowel 
obstruction or malabsorption, kidney transplantation, autosomal 
dominant polycystic kidney disease
Hyperparathyroidism (e.g. PTH levels >2 × upper normal 
defined by the reference values of each participating center)
Body mass index >35 kg/m2
































to occur. The biweekly evaluation of serum phosphate levels en-
sures that hypophosphatemia will be noticed in an early phase. 
Therefore, symptomatic hypophosphatemia is not expected and 
has not occurred so far. If hypophosphatemia is noticed, the dosing 
scheme is adapted per protocol ( table 2 ). Adverse events and vital 
signs are monitored at every study visit.
 Study End Points 
 The primary study end point is the absolute change in cFGF23 
from baseline to end of treatment for the highest (tolerable) dose 
of sevelamer carbonate. The secondary end point is decline in 
cFGF23 from baseline to end of treatment per stage of CKD. 
 Other prespecified explorative variables include plasma levels 
of  creatinine, phosphate, albumin, calcium, 25(OH) 2 D and 
1,25(OH) 2 D 3 and PTH. Twenty-four hours urine collections were 
used for measurements of phosphate and calcium excretion and 
proteinuria. In addition, creatinine clearance and TmP/GFR were 
calculated.
 Sample Size 
 Formal sample size calculations are not possible due to lack of 
sufficient data in the literature. However, based on the study of 
Oliveira et al.  [31], an approximately 50% decline of intact FGF23 
is anticipated in the 6,400 mg dose of sevelamer, which was statis-
tically significant in 21 patients in stage III CKD. Since it is un-
known if cFGF23 response might be different, we aim at 45 pa-
tients to complete the protocol, to detect a significant effect on 
cFGF23 on the highest dose of 8,000 mg/day. Since a 25% dropout 
can be expected, based on previous studies using sevelamer, 60 pa-
tients will be recruited aiming at equal distribution for stages of 
CKD.
 Fig. 1. Medication titration schedule of the SoFT study. 





>0.8 Proceed to next dose level
0.7–0.8 No dose increase
0.6–0.7 Dose reduction to previous level
<0.6 Stop sevelamer for 2 weeks, resume 
sevelamer at lower dose level
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 Statistical Analysis 
 We will use standard descriptive statistics to assess baseline 
clinical and laboratory data at enrolment. Statistical analysis of 
the primary end point will be performed using Generalize Esti-
mating Equations, a technique suitable for longitudinal data 
analysis, using current versions of SPSS version 22, Stata version 
14 and  MLwiN version 2.36. Adjustments for stage of CKD and 
sevelamer dose will be made. In general, p < 0.05 will be consid-
ered to be statistically significant. Patients who dropout during 
the study period will be analyzed until the last hospital visit at 
which data have been collected, except for dropout due to screen-
ing failure.
 Trial Status 
 Patient enrolment started at February 2014; the expected date 
of last patient enrolment will be mid-2017. The study will end 18 
weeks after the last patient enrolment.
 Currently, 20 participants are included of which 17 participants 
completed the study and there were 3 dropouts. Forty-five percent 
were men, the mean age was 58 ± 14 years and 5 participants had 
an eGFR between 60 and 89 ml/min/1.73 m 2 and 15 participants 
had an eGFR between 30 and 59 ml/min/1.73 m 2 . None of them 
had an eGFR between 5–29 or  ≥ 90 ml/min/1.73 m 2 .
 Discussion 
 As pointed out in the introduction, both epidemio-
logical and mechanistic studies consistently point to a 
causal role for FGF23 in CKD-related morbidity. How-
ever, definitive proof of this causal role should come 
from a prospective clinical trial. Principle maneuvers 
currently available to target FGF23 are dietary phos-
phate restriction, phosphate binding therapy and calci-
mimetic therapy, with the latter option not routinely 
available for predialysis CKD patients. Data on the 
FGF23-lowering effect of the various types of phosphate 
binders appear to be most consistent for sevelamer  [28, 
31, 32, 36–40] . Calcium-based phosphate binders may 
not reduce or may even increase FGF23  [28, 39, 41] . 
However, no formal dose–response relationship be-
tween sevelamer carbonate and FGF23 has been estab-
lished. Moreover, there is no data on the uptitration of 
sevelamer carbonate beyond the point of reaching nor-
mal serum phosphate concentrations that may induce a 
further decline in FGF23. Data from the SoFT trial are 
required before initiating a prospective trial aimed at re-
duction of clinical end points by targeting FGF23 in pa-
tients with CKD.
 Clinical Trial Registration 
 2012-002967-84 (EudraCT number), NL40300.029.13 (Dutch 
Trial Register). 
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